Abbott (NYSE:ABT) today said it launched a new bundle with Withings for its Lingo over-the-counter glucose biosensor at Best Buy. Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre continuous glucose monitor (CGM) technology platform. The consumer […]
Diabetes
Beta Bionics introduces new insights feature with automated insulin delivery tech
Beta Bionics (Nasdaq:BBNX) announced today that it launched Bionic Insights, a new feature for healthcare providers and people with diabetes. The new feature further bolsters the company’s iLet automated insulin delivery system platform. Meanwhile, the company looks poised to add further offerings with the planned “Mint” patch pump, eyeing on a 2027 launch. Irvine, California-based […]
Analysts initiate MiniMed with ‘Buy’ rating in competitive diabetes tech space
BTIG analysts today opened coverage for MiniMed (Nasdaq:MMED) with optimism about the company’s scale, reach and potential pipeline. Marie Thibault, Alexandra Pang and Sam Eiber initiated MiniMed with a “Buy” rating following the Medtronic Diabetes business’ recent initial public offering (IPO), despite the IPO coming up short of its initial target price. “Our MiniMed Group […]
Insulet picks longtime Stryker leader as new chief commercial officer
Insulet (Nasdaq:PODD) announced today that it appointed Mike Panos as EVP, chief commercial officer (CCO), effective immediately. In this role, Panos takes responsibility for the Acton, Massachusetts-based automated insulin delivery system developer’s global commercial organization. He reports to President and CEO Ashley McEvoy and serves on the executive leadership team. Panos brings 30 years of […]
Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2
Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor (CBGM). The Glucotrack device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, […]
Novo Nordisk gets FDA nod for Awiqli once-weekly basal insulin for type 2 diabetes
Novo Nordisk announced today that it received FDA approval for Awiqli, the first and only once-weekly, long-acting basal insulin. Awiqli (insulin icodec-abae) injection 700 units/mL, is indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes. Approval grants people with type 2 diabetes a […]
Vivani advances development of semaglutide implant
Vivani Medical (Nasdaq:VANI) provided updates this week on its progress and plans related to NPM-139, the company’s semaglutide implant. Alameda, California-based Vivani completed LIBERATE-1, which evaluated its miniature GLP-1 implant in obese and overweight subjects. The company initiated its LIBERATE-1 trial at two centers in Australia at the end of 2024. This study followed FDA […]
Vaxess rebrands to Terrestrial Bio, raises $50M for GLP-1 patch
Vaxess Technologies today announced a rebranding to Terrestrial Bio, Inc., along with $50 million in Series C financing. Boston-based Terrestrial Bio rebranded to reflect its strategic focus on transforming the delivery and accessibility of its therapies. That starts with GLP-1 therapeutics, delivered using the company’s microarray patch (MAP). The technology features a soluble microarray with […]
Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval
Medtronic (NYSE:MDT) said in an SEC filing that it lowered its full-year guidance after a one-time charge related to its MiniMed diabetes unit. Last week, MiniMed announced FDA clearance for the MiniMed Flex, a next-generation automated insulin delivery system. Clearance came “several months earlier than anticipated,” according to the filing, facilitating earlier commercialization. R&D for […]
Tandem Diabetes Care reports positive findings for Control-IQ in low-bolusing youths
Tandem Diabetes Care (Nasdaq:TNDM) has shared new findings supporting the use of its Control-IQ technology in type 1 diabetes. San Diego-based Tandem’s study aimed to assess the differences in time in range (TIR) between automated insulin delivery (AID) systems in youth with low bolus frequency. It compared Tandem Control-IQ technology with an undisclosed disposable patch-based […]
